3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
243
Squamous Cell Carcinoma of Head and Neck
137
Melanoma
137
Parkinson Disease 4, Autosomal Dominant Lewy Body
119
Neoplasm Metastasis
105
Triple Negative Breast Neoplasms
96
Neoplasms
90
Lung Neoplasms
88
Breast Neoplasms
79
Colorectal Neoplasms
70
Carcinoma, Renal Cell
69
Head and Neck Neoplasms
59
Urinary Bladder Neoplasms
50
Stomach Neoplasms
48
Ovarian Neoplasms
46
Endometrial Neoplasms
45
Carcinoma, Transitional Cell
44
Carcinoma, Hepatocellular
35
Uterine Cervical Neoplasms
34
Pancreatic Neoplasms
34
Esophageal Neoplasms
27
Recurrence
25
Prostatic Neoplasms
25
Carcinoma, Squamous Cell
25
Carcinoma
25
Sarcoma
24
Brain Neoplasms
23
Glioblastoma
22
Hodgkin Disease
19
Cholangiocarcinoma
19
Interventions
Nivolumab
4
Ipilimumab
3
Specimen Handling
2
Proton Therapy
2
Magnetic Resonance Spectroscopy
2
Cetuximab
2
tazemetostat
1
spartalizumab
1
pembrolizumab
1
nilotinib
1
atezolizumab
1
Zoledronic Acid
1
X-Rays
1
Tiragolumab
1
Surveys and Questionnaires
1
Radiotherapy
1
Radiosurgery
1
Phantoms, Imaging
1
Imatinib Mesylate
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Chordoma
×
pembrolizumab
×
1 year
×
Clear all
NCT04670679
2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1
Active not recruiting
90 enrolled